Shenzhen Key Laboratory of Nanozymes and Translational Cancer Research, Department of Otolaryngology, Shenzhen Institute of Translational Medicine, The First Affiliated Hospital of Shenzhen University, Shenzhen Second People's Hospital, Shenzhen, 518035, People's Republic of China.
Department of Nephrology, Shenzhen Longgang Central Hospital, Shenzhen, 518116, People's Republic of China.
Int J Nanomedicine. 2024 Jun 19;19:6253-6277. doi: 10.2147/IJN.S459710. eCollection 2024.
The tumor microenvironment (TME) is a complex and dynamic entity, comprising stromal cells, immune cells, blood vessels and extracellular matrix, which is intimately associated with the occurrence and development of cancers, as well as their therapy. Utilizing the shared characteristics of tumors, such as an acidic environment, enzymes and hypoxia, researchers have developed a promising cancer therapy strategy known as responsive release of nano-loaded drugs, specifically targeted at tumor tissues or cells. In this comprehensive review, we provide an in-depth overview of the current fundamentals and state-of-the-art intelligent strategies of TME-responsive nanoplatforms, which include acidic pH, high GSH levels, high-level adenosine triphosphate, overexpressed enzymes, hypoxia and reductive environment. Additionally, we showcase the latest advancements in TME-responsive nanoparticles. In conclusion, we thoroughly examine the immediate challenges and prospects of TME-responsive nanopharmaceuticals, with the expectation that the progress of these targeted nanoformulations will enable the exploitation, overcoming or modulation of the TME, ultimately leading to significantly more effective cancer therapy.
肿瘤微环境(TME)是一个复杂而动态的实体,包含基质细胞、免疫细胞、血管和细胞外基质,与癌症的发生、发展及其治疗密切相关。研究人员利用肿瘤的共同特征,如酸性环境、酶和缺氧,开发了一种有前途的癌症治疗策略,称为纳米载药的响应性释放,专门针对肿瘤组织或细胞。在这篇全面的综述中,我们深入概述了 TME 响应性纳米平台的当前基础和最新智能策略,包括酸性 pH 值、高 GSH 水平、高水平三磷酸腺苷、过表达酶、缺氧和还原环境。此外,我们展示了 TME 响应性纳米颗粒的最新进展。总之,我们彻底检查了 TME 响应性纳米药物的当前挑战和前景,期望这些靶向纳米制剂的进展将能够利用、克服或调节 TME,最终导致更有效的癌症治疗。
J Biomater Sci Polym Ed. 2024-10
Adv Healthc Mater. 2021-3
Adv Drug Deliv Rev. 2021-12
Int J Nanomedicine. 2024
Naunyn Schmiedebergs Arch Pharmacol. 2025-8-12
Drug Deliv Transl Res. 2025-8-11
J Nanobiotechnology. 2025-7-19
Pharmaceuticals (Basel). 2025-5-19
Theranostics. 2025-2-10
ACS Nano. 2023-12-12
J Nanobiotechnology. 2023-9-16
Mater Today Bio. 2023-8-11
Angew Chem Int Ed Engl. 2023-8-1
Cancer Cell. 2023-3-13
Signal Transduct Target Ther. 2023-2-17